查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014688

基因检测市场：2026-2032年全球市场预测（按产品类型、检测类型、技术、应用、分销管道和最终用户划分）

Genetic Testing Market by Product, Test Type, Technology, Application, Distribution Channel, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因检测市场价值将达到 154.4 亿美元，到 2026 年将成长到 176 亿美元，到 2032 年将达到 397.2 亿美元，复合年增长率为 14.44%。

主要市场统计数据
基准年 2025 154.4亿美元
预计年份：2026年 176亿美元
预测年份 2032 397.2亿美元
复合年增长率 (%) 14.44%

全面实施基因检测生态系统，重点在于临床整合、消费者参与、监管发展和营运扩充性。

基因检测领域正经历快速发展，这主要得益于分子技术的进步、临床应用的拓展以及消费者对个人化医疗日益增长的需求。诊断实验室、医院和直接面向消费者的销售管道正在将先进的检测方法整合到其工作流程中，同时，软体和服务也日益支持对检测结果的解读、报告和长期数据管理。这些趋势的融合正在重塑医疗服务提供者、保险公司和患者获取基因资讯的方式。

遗传学领域的变革性变化是由整合测试平台、云端原生解读、不断发展的交付模式和增强的法规结构所驱动的。

基因检测领域正从孤立的检测转向整合的、数据驱动的服务，这些服务融合了检查室能力、分析软体和持续的临床决策支援。定序和PCR平台正与基因表现和微阵列工具相辅相成，而基于云端的生物资讯学正在加速检测结果的交付并提高突变分析的准确性。这些技术的融合使得更全面的诊断方案成为可能，并促进了贯穿整个临床路径的多模态检测策略。

评估 2025 年关税措施如何重组基因检测相关人员的采购、供应链和业务永续营运。

美国2025年实施的关税政策，为整个基因检测生态系统的采购、供应链策略和成本管理引入了新的变数。仪器和耗材製造商被迫重新评估其筹资策略，检测实验室也需要评估进口试剂和设备的总到岸成本。为此，相关人员正在重新分配采购数量，加强供应商多元化，并探索在地化生产方案，以减轻关税相关价格波动的影响。

深入了解全面的细分，以便在技术、测试类型、应用、通路和最终用户方面协调产品开发、商业化和营运重点。

深入了解市场区隔对于制定产品策略和确定投资优先顺序至关重要。从产品类型角度来看，相关人员需要区分驱动持续收入和资本支出週期的耗材和设备，以及透过分析、报告和工作流程整合来建立长期客户关係的软体和服务。每个产品类型都有不同的市场准入要求和服务架构。

从区域观点看美洲、欧洲、中东和非洲以及亚太市场在监管差异、实施速度和供应链本地化方面的细微差别。

区域趋势持续对技术采纳曲线、监管预期和伙伴关係策略产生显着影响。在美洲，科技融入临床实践以及消费者意识的提升正在推动对多样化检测组合的需求，而相关人员则受益于完善的报销机制和紧密的临床网络，这些机制和网络为创新诊断技术的试验提供了支持。随着医疗模式向整合式医疗模式转变，医疗机构正日益将基因组分析成果融入慢性病管理和肿瘤治疗路径中，这反过来又推动了对本地检测能力和结果解读服务的投资。

主要企业透过平台整合、伙伴关係、资料互通性和卓越营运展现策略差异化的趋势。

基因检测领域的竞争格局由成熟的仪器製造商、专业的检测方法开发公司、生物资讯学提供者和综合服务实验室组成。主要参与者透过平台广度、分析演算法和附加价值服务（例如变异註释、真实世界数据 (RWE) 生成和临床医生培训）来脱颖而出。随着互通性和数据标准的重要性日益凸显，投资强大的应用程式介面 (API) 和电子健康记录(EHR) 整合的公司正在临床环境中获得竞争优势。

针对平台柔软性、供应链弹性、资料互通性、监管参与和建构持续临床服务等方面的经营团队实用建议。

产业领导企业应采取多管齐下的策略，以确保其在基因检测领域的长期地位和影响力。首先，应优先投资模组化平台，以便快速引入新的检测方法并提供灵活的服务层级。这将缩短新兴临床应用的上市时间，并支援面向不同类型客户的扩充性。其次，供应商应多元化和区域采购制度化，以减轻关税和物流中断的影响，同时确保品质和检验进度。

采用稳健的混合调查方法，结合相关人员访谈、文献整合、检验和专家同行评审，确保获得实用且检验的见解。

本分析的调查方法结合了定性和定量方法，旨在得出可操作且可重复的见解。主要研究包括对实验室主任、医院采购经理、临床遗传学家和企业高管进行结构化访谈，以了解他们对技术选择、报销挑战和营运重点的第一手观点。次要研究涵盖了同行评审文献、技术白皮书、监管指导文件和公开的企业资讯披露，以将主要研究结果置于更广阔的背景中，并确保其符合当代标准。

总结结论，整合了负责任的实施、营运严谨性、监管合作以及伙伴关係为主导的基因检测成长所面临的策略挑战。

总而言之，基因检测领域正处于一个转折点，技术成熟、监管完善和医疗模式不断演进三者交汇融合，创造了重要的策略机会。那些将产品开发与检验的临床效用相结合、投资于可互通的数据基础设施并增强供应链韧性的机构，将最有利于获得长期价值。同时，与监管机构积极合作以及严谨的证据收集对于扩大临床应用和确保永续的报销途径仍然至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 基因检测市场：依产品划分

  • 耗材/设备
  • 软体服务

第九章 基因检测市场：检测类型

  • 基因带原检测
  • 诊断测试
  • 新生儿筛检
  • 药物基因体学
  • 胚胎着床前检测
  • 产前检查
  • 无症状/预测性检测

第十章 基因检测市场：依技术划分

  • 细胞遗传学
  • DNA定序
  • 基因表现分析
  • 微阵列
  • PCR

第十一章：基因检测市场：依应用领域划分

  • 自体免疫疾病
  • 癌症
  • 慢性病
  • 遗传性疾病
  • 神经退化性疾病

第十二章 基因检测市场：依分销管道划分

  • 离线
  • 在线的

第十三章：基因检测市场：依最终用户划分

  • 诊断检查室
  • 家庭环境
  • 医院和诊所

第十四章 基因检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 基因检测市场：依群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 基因检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国基因检测市场

第十八章：中国基因检测市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Bruker Corporation
  • Centogene NV
  • Color Health, Inc.
  • CooperSurgical Inc.
  • Editas Medicine, Inc.
  • Eugene Labs Pty Ltd.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Fulgent Genetics, Inc.
  • Gene by Gene, Ltd.
  • GeneDx, LLC
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Living DNA Ltd.
  • Macrogen, Inc.
  • MyHeritage Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Newtopia Inc.
  • PathogenDx Corporation
  • PerkinElmer Inc.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-437E9896A512

The Genetic Testing Market was valued at USD 15.44 billion in 2025 and is projected to grow to USD 17.60 billion in 2026, with a CAGR of 14.44%, reaching USD 39.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.44 billion
Estimated Year [2026] USD 17.60 billion
Forecast Year [2032] USD 39.72 billion
CAGR (%) 14.44%

An expansive introduction to the genetic testing ecosystem emphasizing clinical integration, consumer engagement, regulatory evolution, and operational scalability

The genetic testing landscape is undergoing a period of rapid refinement driven by advances in molecular technologies, expanded clinical applications, and heightened consumer interest in personalized health. Diagnostic laboratories, hospitals, and direct-to-consumer channels are integrating sophisticated assays into workflows, while software and services increasingly enable interpretation, reporting, and longitudinal data management. These converging trends are reshaping how providers, payers, and patients interact with genetic information.

Moreover, regulatory agencies and professional societies are clarifying standards for analytic validity, clinical utility, and data privacy, which in turn influence adoption patterns across clinical and consumer settings. Operational scalability remains a parallel priority as laboratories balance throughput, quality control, and supply chain resilience. As stakeholders navigate these dynamics, strategic choices around technology platforms, test portfolios, and distribution models will determine competitive positioning and the ability to capture clinical value. Consequently, stakeholders should prioritize rigorous validation, clear clinical pathways, and interoperable data infrastructures that support integration with electronic health records and value-based care initiatives.

Transformative shifts in genetics driven by integrated laboratory platforms, cloud-native interpretation, evolving delivery models, and strengthened regulatory frameworks

The landscape of genetic testing is shifting from siloed assays toward integrated, data-driven offerings that combine laboratory capabilities with interpretive software and ongoing clinical decision support. Sequencing and PCR-based platforms are being complemented by gene expression and microarray tools, while cloud-enabled bioinformatics is accelerating turnaround and enhancing variant interpretation. These technological convergences enable more comprehensive diagnostic panels and foster multi-modal testing strategies across clinical pathways.

Concurrently, market actors are rethinking delivery models. Diagnostic laboratories and hospitals are optimizing in-house testing for high-acuity needs, while outsourced partners and software vendors provide specialized services and analytics. Direct-to-consumer access continues to expand awareness of genetic health, prompting clinicians and payers to refine utility frameworks. Regulatory and reimbursement trends are encouraging standardized reporting and evidence generation, which in turn support broader clinical adoption. Ultimately, the most transformative shifts balance technological innovation with validated clinical utility, robust data governance, and sustainable operational models.

Assessment of how the 2025 tariff measures have reshaped procurement, supply chains, and operational resilience for genetic testing stakeholders

The imposition of tariffs by the United States in 2025 has introduced new variables into procurement, supply chain strategy, and cost management across the genetic testing ecosystem. Manufacturers of instruments and consumables have had to reassess sourcing strategies, and laboratories have been prompted to evaluate the total landed cost of imported reagents and equipment. In response, stakeholders are reallocating purchasing volumes, intensifying supplier diversification, and seeking regional manufacturing options to mitigate exposure to tariff-related price fluctuations.

These adjustments are cascading through operational planning. Some laboratories are lengthening inventory reorder cycles and strengthening supplier contracts to buffer against potential customs delays. Others are accelerating validation of alternative platforms that rely on different component mixes or domestic supply chains. At the same time, strategic collaborations between vendors and laboratories are being used to share risk, co-develop localized supply solutions, and provide bundled service agreements that reduce transactional vulnerabilities. Looking ahead, tariff-related pressures are likely to reinforce the value of supply chain transparency, dual-sourcing, and client-vendor partnerships that prioritize continuity of clinical testing services.

Comprehensive segmentation insights to align product development, commercialization, and operational priorities across technologies, test types, applications, channels, and end users

A granular understanding of market segmentation is essential for designing product strategies and prioritizing investments. When viewed through the lens of product categories, stakeholders must differentiate between consumables and equipment, which drive recurring revenue and capital expenditure cycles, and software and services, which create long-term client relationships through analytics, reporting, and workflow integration. Each product category imposes different go-to-market requirements and service architectures.

Considering test type segmentation, payer acceptance and clinical workflows vary significantly across carrier testing, diagnostic testing, newborn screening, pharmacogenomics, preimplantation testing, prenatal testing, and presymptomatic and predictive testing. Consequently, product development should be tailored to the unique evidentiary and regulatory expectations of each test type. From a technology standpoint, choices among cytogenetics, DNA sequencing, gene expression profiling, microarrays, and PCR influence assay sensitivity, throughput, and cost-per-test, and should align with intended clinical or consumer applications.

Application-oriented segmentation reveals differing demand dynamics across autoimmune disorders, cancer, chronic diseases, genetic disorders, and neurodegenerative diseases, each requiring distinct validation datasets and clinical decision frameworks. Distribution channel distinctions between offline and online models determine how tests are marketed, consented, and delivered, while end-user segmentation-diagnostic laboratories, home setting, and hospitals and clinics-shapes service level requirements, integration needs, and training obligations. Together, these segment perspectives provide a roadmap for aligning R&D, commercial, and operational priorities to real-world pathways of adoption.

Regional perspectives on regulatory nuance, adoption velocity, and supply chain localization across the Americas, Europe Middle East Africa, and Asia-Pacific markets

Regional dynamics continue to exert strong influence on adoption curves, regulatory expectations, and partnership strategies. In the Americas, clinical integration and consumer awareness are both driving demand for diverse testing portfolios, and stakeholders benefit from established reimbursement pathways and dense clinical networks that support trialing innovative diagnostics. Transitioning toward integrated care models, institutions are increasingly incorporating genomic insights into chronic disease management and oncology pathways, which in turn encourages investment in local laboratory capabilities and interpretive services.

Across Europe, the Middle East, and Africa, heterogeneity in regulatory frameworks and healthcare infrastructure yields a mosaic of opportunities. Some jurisdictions emphasize centralized newborn screening and national genomic initiatives, while others are scaling private laboratory services. This variability requires adaptive market entry strategies that accommodate differing certification requirements and data protection norms. Meanwhile, in the Asia-Pacific region, rapid technology adoption and expanding clinical laboratory capacity are supporting growth in both hospital-based testing and consumer-facing services. Regional supply chains and manufacturing hubs are also maturing, offering opportunities to localize production and reduce dependence on cross-border logistics. Taken together, these regional characteristics necessitate tailored commercial models, regulatory engagement, and localized partnerships to achieve sustainable adoption.

Key company dynamics revealing strategic differentiation through platform integration, partnerships, data interoperability, and operational excellence

Competitive dynamics in genetic testing are shaped by a mix of incumbent instrument manufacturers, specialized assay developers, bioinformatics providers, and integrated service laboratories. Leading actors are differentiating through platform breadth, interpretive algorithms, and value-added services such as variant curation, real-world evidence generation, and clinician education. As interoperability and data standards become more critical, companies that invest in robust APIs and EHR integration gain a competitive edge in clinical settings.

Strategic approaches also vary: some firms prioritize vertical integration by combining instrumentation, consumables, and proprietary assays to capture margin across the value chain, while others focus on partnerships and open-platform strategies that accelerate adoption through third-party validations. In addition, alliance-building with hospital systems, academic centers, and payers supports evidence development and aids in securing coverage pathways. Finally, operational excellence-demonstrated through consistent quality metrics, scalable logistics, and responsive customer support-remains a decisive factor for laboratories and health systems when selecting vendor partners.

Actionable recommendations for executives to build platform flexibility, supply chain resilience, data interoperability, regulatory engagement, and recurring clinical services

Industry leaders should adopt a multi-pronged approach to secure long-term relevance and influence in genetic testing. First, prioritize investments in modular platforms that allow rapid adoption of new assays and enable flexible service tiers; this reduces time-to-market for emerging clinical applications and supports scalability across diverse client types. Second, institutionalize supplier diversification and regional sourcing to mitigate tariff and logistics disruptions while preserving quality and validation timelines.

Third, elevate data stewardship and interoperability by implementing standardized reporting formats, API-driven integrations with electronic health records, and transparent variant interpretation frameworks that can be audited by external stakeholders. Fourth, engage proactively with regulators, payers, and professional societies to co-develop evidence generation strategies that demonstrate clinical utility and inform coverage policies. Fifth, expand service offerings beyond raw testing to include longitudinal patient monitoring, clinician decision support, and curated databases that create recurring revenue and strengthen client relationships. Together, these actions will position organizations to capitalize on clinical demand while managing operational risk and regulatory complexity.

Robust mixed-methods research methodology combining stakeholder interviews, literature synthesis, triangulation, and expert peer review to ensure practical and validated insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches to produce actionable, reproducible insights. Primary research included structured interviews with laboratory directors, hospital procurement leads, clinical geneticists, and commercial executives to surface first-hand perspectives on technology choice, reimbursement challenges, and operational priorities. Secondary research encompassed peer-reviewed literature, technical white papers, regulatory guidance documents, and publicly available corporate disclosures to contextualize primary findings and ensure alignment with contemporary standards.

Data synthesis employed triangulation techniques to reconcile divergent stakeholder views and to validate thematic findings against documented practice patterns. The methodology emphasized transparency: testing modalities were mapped against clinical pathways, and segmentation schemas were cross-checked with stakeholder interviews to ensure practical relevance. Where applicable, sensitivity checks were used to examine the robustness of conclusions under alternative operational scenarios. Finally, findings were peer-reviewed by subject matter experts with clinical and laboratory leadership experience to ensure accuracy and real-world applicability.

Conclusion synthesizing strategic imperatives for responsible adoption, operational rigor, regulatory engagement, and partnership-driven growth in genetic testing

In summary, the genetic testing sector stands at an inflection point where technological maturity, regulatory refinement, and evolving care models intersect to create significant strategic opportunities. Organizations that align product development with validated clinical utility, invest in interoperable data infrastructure, and strengthen supply chain resilience will be best positioned to capture long-term value. At the same time, proactive regulatory engagement and rigorous evidence generation remain essential to expand clinical adoption and ensure sustainable reimbursement pathways.

Looking ahead, success will favor entities that balance innovation with operational rigor, cultivate partnerships across clinical and commercial stakeholders, and design services that integrate seamlessly into existing care workflows. By focusing on these priorities, market participants can accelerate responsible adoption of genetic testing technologies, improve patient outcomes, and build resilient business models that withstand regulatory and macroeconomic headwinds.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genetic Testing Market, by Product

  • 8.1. Consumables & Equipment
  • 8.2. Software & Services

9. Genetic Testing Market, by Test Type

  • 9.1. Carrier Testing
  • 9.2. Diagnostic Testing
  • 9.3. New Born Screening
  • 9.4. Pharmacogenomics
  • 9.5. Preimplantation Testing
  • 9.6. Prenatal Testing
  • 9.7. Presymptomatic & Predictive Testing

10. Genetic Testing Market, by Technology

  • 10.1. Cytogenetics
  • 10.2. DNA Sequencing
  • 10.3. Gene Expression Profiling
  • 10.4. Microarrays
  • 10.5. PCR

11. Genetic Testing Market, by Application

  • 11.1. Autoimmune Disorders
  • 11.2. Cancer
  • 11.3. Chronic Diseases
  • 11.4. Genetic Disorders
  • 11.5. Neurodegenerative Diseases

12. Genetic Testing Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Genetic Testing Market, by End-User

  • 13.1. Diagnostic Laboratories
  • 13.2. Home Setting
  • 13.3. Hospitals & Clinics

14. Genetic Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Genetic Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Genetic Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Genetic Testing Market

18. China Genetic Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Agilent Technologies, Inc.
  • 19.7. Becton, Dickinson and Company
  • 19.8. Bio-Rad Laboratories, Inc.
  • 19.9. Bio-Techne Corporation
  • 19.10. Bruker Corporation
  • 19.11. Centogene N.V.
  • 19.12. Color Health, Inc.
  • 19.13. CooperSurgical Inc.
  • 19.14. Editas Medicine, Inc.
  • 19.15. Eugene Labs Pty Ltd.
  • 19.16. Eurofins Scientific SE
  • 19.17. F. Hoffmann-La Roche AG
  • 19.18. Fulgent Genetics, Inc.
  • 19.19. Gene by Gene, Ltd.
  • 19.20. GeneDx, LLC
  • 19.21. Illumina, Inc.
  • 19.22. Invitae Corporation
  • 19.23. Laboratory Corporation of America Holdings
  • 19.24. Living DNA Ltd.
  • 19.25. Macrogen, Inc.
  • 19.26. MyHeritage Ltd.
  • 19.27. Myriad Genetics, Inc.
  • 19.28. Natera, Inc.
  • 19.29. Newtopia Inc.
  • 19.30. PathogenDx Corporation
  • 19.31. PerkinElmer Inc.
  • 19.32. Qiagen N.V.
  • 19.33. Quest Diagnostics Incorporated
  • 19.34. Sanofi S.A.
  • 19.35. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENETIC TESTING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENETIC TESTING MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENETIC TESTING MARKET SIZE, BY CONSUMABLES & EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENETIC TESTING MARKET SIZE, BY CONSUMABLES & EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENETIC TESTING MARKET SIZE, BY CONSUMABLES & EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENETIC TESTING MARKET SIZE, BY CARRIER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENETIC TESTING MARKET SIZE, BY CARRIER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENETIC TESTING MARKET SIZE, BY CARRIER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENETIC TESTING MARKET SIZE, BY NEW BORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENETIC TESTING MARKET SIZE, BY NEW BORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENETIC TESTING MARKET SIZE, BY NEW BORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENETIC TESTING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENETIC TESTING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENETIC TESTING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENETIC TESTING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENETIC TESTING MARKET SIZE, BY PRESYMPTOMATIC & PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENETIC TESTING MARKET SIZE, BY PRESYMPTOMATIC & PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENETIC TESTING MARKET SIZE, BY PRESYMPTOMATIC & PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENETIC TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENETIC TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENETIC TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENETIC TESTING MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENETIC TESTING MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENETIC TESTING MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENETIC TESTING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENETIC TESTING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENETIC TESTING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENETIC TESTING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENETIC TESTING MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENETIC TESTING MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENETIC TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENETIC TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENETIC TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENETIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENETIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENETIC TESTING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENETIC TESTING MARKET SIZE, BY CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENETIC TESTING MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENETIC TESTING MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENETIC TESTING MARKET SIZE, BY CHRONIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENETIC TESTING MARKET SIZE, BY CHRONIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENETIC TESTING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENETIC TESTING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENETIC TESTING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENETIC TESTING MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENETIC TESTING MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENETIC TESTING MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENETIC TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENETIC TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENETIC TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENETIC TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENETIC TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENETIC TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENETIC TESTING MARKET SIZE, BY HOME SETTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENETIC TESTING MARKET SIZE, BY HOME SETTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENETIC TESTING MARKET SIZE, BY HOME SETTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GCC GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. GCC GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. GCC GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 166. G7 GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. G7 GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. G7 GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. G7 GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. G7 GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. G7 GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. NATO GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. NATO GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. NATO GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. NATO GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. NATO GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA GENETIC TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA GENETIC TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)